Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
about
Retinoid-xenobiotic interactions: the Ying and the YangRole of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and CancerIdentification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy ModelDevelopment and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.Inhibition of the all-trans Retinoic Acid (atRA) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous atRA Signaling.Improved Homology Model of the Human all-trans Retinoic Acid Metabolizing Enzyme CYP26A1.WNT4 acts downstream of BMP2 to mediate the regulation of ATRA signaling on RUNX1 expression: Implications for terminal differentiation of antler chondrocytes.Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase α.Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids.Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions.Climbazole boosts activity of retinoids in skin.13cRA regulates the differentiation of antler chondrocytes through targeting Runx3.Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.Expression and regulation of Angiopoietins and their receptor Tie-2 in sika deer antlerAssociation study between novel CYP26 polymorphisms and the risk of betel quid-related malignant oral disorders
P2860
Q26796662-C4F64456-E3F8-4819-AFFB-4C65858428B3Q26800202-6E77305E-88CA-4FD2-B40B-139CFAC5AA5FQ28115020-C21AD45C-2FFC-4EC2-ACE0-FF252C5BA056Q36256005-B3224316-F605-44AF-858E-5DFC2510F748Q38790863-B302CDD7-FB6E-4CAE-8AFD-6FE7A1F45512Q38818104-1EF335CB-4342-4E8D-A9AB-E183D420A9CAQ39902041-84374FF6-331A-4CF1-8AAC-D8B35A3B8FC6Q48242791-AD398C33-2794-4277-B8A2-6EF0B8C152B8Q49315313-54AE55A0-BA37-47D3-A65B-691FAD6F706BQ49538563-615E414C-3EBC-4ACB-986D-9A731A55EA9EQ51105253-9310A57E-3314-4159-B1AD-2138B859F686Q51181348-A6E86451-BAE4-4B65-B373-610C59FF3FDDQ51206203-138D5141-B361-4265-919C-30FCD2F448E1Q51636744-AD4112A1-B1A3-494B-9A26-7218A59F0596Q58133737-A07EC025-2820-4402-AF25-304E5AD9A804Q59121142-983BD45E-794A-42EB-88F3-876DF64447F3
P2860
Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@ast
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@en
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@nl
type
label
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@ast
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@en
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@nl
prefLabel
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@ast
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@en
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@nl
P2093
P2860
P1476
Therapeutic potential of the i ...... A1 and CYP26B1 by xenobiotics.
@en
P2093
Brian R Buttrick
Cara H Nelson
Nina Isoherranen
P2860
P304
P356
10.2174/1568026611313120004
P577
2013-01-01T00:00:00Z